Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discov. 2020 01; 10(1):40-53.
View in:
PubMed
subject areas
Adult
Aged
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Renal Cell
Drug Resistance, Neoplasm
Female
Follow-Up Studies
Furans
Humans
Kidney Neoplasms
Male
Middle Aged
Neoplasm Recurrence, Local
Prognosis
Pyridines
Pyrimidines
Receptor, Adenosine A2A
Salvage Therapy
Survival Rate
authors with profiles
Philip Bonomi